Scale-Up Of An ELEVECTA Transient rAAV8 Production Process In The Xcellerex X-Platform Single-Use Bioreactor

By T Falkman, J Viiliäinen, KE Cybulski, B Hudjetz, M Mühle, and T Erlandson

Scaling rAAV production without compromising quality remains a major hurdle for gene therapy developers. Advances in suspension-based cell culture are helping address this challenge, enabling higher cell densities and more efficient vector yields across multiple serotypes. Recent process scaling demonstrates consistent performance from bench to larger volumes, maintaining comparable culture behavior and titers while reducing encapsidated host cell DNA. Integrating a high-performing transient cell line with single-use bioreactor technology and optimized, GMP-grade media creates a streamlined path from early R&D through commercial manufacturing. For teams focused on translating promising therapies into scalable realities, these process insights highlight practical approaches to improving productivity, consistency, and product quality at scale.

See how these strategies can strengthen your next step toward robust rAAV manufacturing.